Tabor E, Buynak E, Smallwood L A, Snoy P, Hilleman M, Gerety R J
J Med Virol. 1983;11(1):1-9. doi: 10.1002/jmv.1890110102.
Dilutions of human sera containing between 10(3) and 10(5) chimpanzee infectious doses of hepatitis B virus per ml, subtype adr or ayw, were treated with either 1 microgram/ml pepsin at pH 2.0 for 18 hours, 8 M urea for four hours, or 1:4,000 formalin for 72 hours. One ml of the serum containing hepatitis B virus subjected to each of the procedures was inoculated intravenously into one or two susceptible chimpanzees (total of eight chimpanzees). No evidence of hepatitis B infection was detected in weekly serum samples from the chimpanzees during six months of observation. These three procedures are currently applied during manufacture to inactivate HBV which might be present in the hepatitis B vaccine licensed in the United States. The data from this study combined with data documenting that the physical purification of the vaccine is capable of removing hepatitis B virus provide assurance that there is no residual live hepatitis B virus in the vaccine.
将每毫升含有10³至10⁵个黑猩猩感染剂量的乙型肝炎病毒(adr或ayw亚型)的人血清稀释液,分别用pH 2.0的1微克/毫升胃蛋白酶处理18小时、8M尿素处理4小时或1:4000福尔马林处理72小时。将经过每种处理的1毫升含乙型肝炎病毒的血清静脉注射到一两只易感黑猩猩体内(共八只黑猩猩)。在六个月的观察期内,从黑猩猩的每周血清样本中未检测到乙型肝炎感染的迹象。目前在生产过程中应用这三种方法来灭活美国许可的乙型肝炎疫苗中可能存在的HBV。这项研究的数据与记录疫苗物理纯化能够去除乙型肝炎病毒的数据相结合,确保了疫苗中没有残留的活乙型肝炎病毒。